NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
Clinical Trials
6 trialsNCT06553339 2024-08-14
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05843305 2023-05-06
A Study of BPI-452080 in Subjects With Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT02108002 2018-09-14
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00089765 2017-07-02
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00056199 2008-03-04
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed